Variables Associated to Pathologic Complete Response, Overall Survival and Disease-Free Survival in the Neoadjuvant Setting for Esophageal Cancer: A Retrospective Cohort Analysis

Carregando...
Imagem de Miniatura
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
INT COLLEGE OF SURGEONS
Citação
INTERNATIONAL SURGERY, v.103, n.3-4, p.214-221, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: The aim of the study was to evaluate prognostic factors during neoadjuvant therapy that can predict pathologic complete response (pCR), overall survival (OS), or disease-free survival (DFS). Summary of background data: Variables that can predict tumor response to neoadjuvant therapy are required for esophageal cancer management. Methods: A retrospective cohort was performed with esophageal cancer patients submitted to neoadjuvant therapy. pCR, OS, and DFS were evaluated. Logistic regression was used to evaluate prognostic factors. This study covered 140 patients, 94 squamous cell carcinomas (SCC), and 44 adenocarcinomas. SCC is more often associated with pCR (compared to adenocarcinoma, OR: 8.07, 95% CI: 2.91-22.38); it has higher probability of DFS (HR for death or recurrence was 0.6, 95% CI: 0.37-0.98); and a higher probability of OS (HR for death was 0.59, 95% CI: 0.35-1). Gender, age, grade of cellular differentiation, chemotherapy regimen, and neoplasm circumferential involvement before neoadjuvant therapy are variables that are unrelated to DFS. Relief of dysphagia, and weight gain were also unrelated to the outcomes. In the multivariate analysis, the weight loss during neoadjuvant therapy was related to higher risk for recurrence or death (HR 1.02, 95% CI: 1-1.04). SCC histologic type was associated with higher probability of pCR, and higher OS and DFS rates. Gender, grade of cellular differentiation, and chemotherapy regimen are variables that are unrelated to pCR, OS, and DFS. Relief of dysphagia and increased levels of albumin after neoadjuvant therapy were also unrelated to the studied outcomes. Weight loss during neoadjuvant chemotherapy was associated with poor DFS rate in the multivariate analysis.
Palavras-chave
Esophageal neoplasms, Neoadjuvant therapy, Prognosis
Referências
  1. Ajani JA, 2015, J NATL COMPR CANC NE, V13, P194, DOI 10.6004/jnccn.2015.0028
  2. Akiyama Y, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1420-8
  3. American Cancer Society, 2018, CANC FACTS FIG 2018
  4. Bollschweiler E, 2010, FUTURE ONCOL, V6, P25, DOI [10.2217/fon.09.133, 10.2217/FON.09.133]
  5. Forshaw MJ, 2006, CLIN ONCOL-UK, V18, P345, DOI 10.1016/j.clon.2006.02.008
  6. HOSMER DW, 2000, WILEY PS TX, P1
  7. Kirkwood BR, 2006, ESSENTIAL MED STAT
  8. KLEINBAUM DG, 1996, SURVIVAL ANAL SELF L
  9. Lee PC, 2009, ANN THORAC SURG, V88, P186, DOI 10.1016/j.athoracsur.2009.03.079
  10. Li CY, 2016, BIOMED RES INT, DOI 10.1155/2016/6423297
  11. Mota FC, 2018, INT J SURG, V54, P176, DOI 10.1016/j.ijsu.2018.04.053
  12. Pasquali S, 2017, ANN SURG, V265, P481, DOI 10.1097/SLA.0000000000001905
  13. Rice TW, 2017, ANN CARDIOTHORAC SUR, V6, P119, DOI 10.21037/acs.2017.03.14
  14. Ripley RT, 2016, ANN THORAC SURG, V101, P226, DOI 10.1016/j.athoracsur.2015.06.062
  15. Roushan Nader, 2014, Med J Islam Repub Iran, V28, P54
  16. Slater MS, 2001, AM J SURG, V181, P440, DOI 10.1016/S0002-9610(01)00601-8
  17. Strandby RB, 2016, SCAND J SURG, V105, P97, DOI 10.1177/1457496915594716
  18. Tepper J, 2008, J CLIN ONCOL, V26, P1086, DOI 10.1200/JCO.2007.12.9593
  19. Tustumi F, 2016, ABCD-ARQ BRAS CIR DI, V29, P138, DOI 10.1590/0102-6720201600030003
  20. TUSTUMI Francisco, 2016, Arq. Gastroenterol., V53, P44, DOI 10.1590/S0004-28032016000100009
  21. van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088
  22. Zemanova M, 2012, J BUON, V17, P310